Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MIW815 |
| Synonyms | |
| Therapy Description |
MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling (STING1), resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787, PMID: 31355488). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MIW815 | ADUS100|ADU-S100|NVP-MIW815 | STING1 Agonist 21 | MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling (STING1), resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787, PMID: 31355488). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02675439 | Phase I | Ipilimumab + MIW815 MIW815 | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |